185629-32-7

Basic information

• Product Name: Methyl-4-amino-3-fluorobenzoate
• Synonyms: Methyl-4-amino-3-fluorobenzoate;2-Fluoro-4-(methoxycarbonyl)aniline;Benzoic acid, 4-aMino-3-fluoro-, Methyl ester;Methyl 3-fluoro-4-aMinobenzoate;3-Fluoro-4-aminobenzoic acid methyl ester
• CAS NO: 185629-32-7
• Molecular Formula: C₈H₈FNO₂
• Molecular Weight: 169.1530232
• Mol File: 185629-32-7.mol
• Article Data: 17

Chemical Properties

• Melting Point: 109-110°C
• Boiling Point: 296℃
• Flash Point: 133℃
• Appearance: /
• Density: 1.264
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Methyl-4-amino-3-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-4-amino-3-fluorobenzoate(185629-32-7)
• EPA Substance Registry System: Methyl-4-amino-3-fluorobenzoate(185629-32-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 22-24/25-36/37/39-45
• HazardClass: IRRITANT
• Hazardous Substances Data: 185629-32-7(Hazardous Substances Data)

Usage

Chemical Properties

Brown solid

InChI:InChI=1/C8H8FNO2/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4H,10H2,1H3

Upstream product

• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 67-56-1 methanol 
• 455-87-8 4-amino-3-fluorobenzoic acid 
• 369-25-5 methyl 3,4-difluorobenzoate 

Downstream Products

• 1123171-91-4 methyl 4-amino-3-bromo-5-fluorobenzoate 
• 1123172-01-9 4-amino-3-fluoro-5-iodobenzoic acid methyl ester 
• 1178898-53-7 C₂₈H₂₄FNO₄ 
• 1178898-54-8 C₂₉H₂₆FNO₄ 
• 1178898-55-9 C₃₀H₂₄FNO₄ 
• 1449410-48-3 methyl 4-{[4-{[1-(4-chlorophenyl)cyclopropyl]amino}-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}-3-fluorobenzoate 
• 1219687-20-3 methyl 4-(chlorosulfonyl)-3-fluorobenzoate 
• 716361-59-0 3-fluoro-4-methanesulfonylaminobenzoic acid 

Relevant articles and documents

Exploring boron applications in modern agriculture: A structure-activity relationship study of a novel series of multi-substitution benzoxaboroles for identification of potential fungicides

Several boron-containing small molecules have been approved by the US FDA to treat human diseases. We explored potential applications of boron-containing compounds in modern agriculture by pursuing multiple research and development programs. Here, we report a novel series of multi-substitution benzoxaboroles (1–36), a compound class that we recently reported as targeting geranylgeranyl transferase I (GGTase I) and thereby inhibiting protein prenylation (Kim et al., 2020). These compounds were designed, synthesized, and tested against the agriculturally important fungal pathogens Mycosphaerella fijiensis and Colletotrichum sublineolum in a structure–activity relationship (SAR) study. Compounds 13, 28, 30, 34 and 36 were identified as active leads with excellent antifungal MIC95 values in the range of 1.56–3.13 ppm against M. fijiensis and 0.78–3.13 ppm against C. sublineolum.

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

FXR receptor agonist

The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.